About Abionyx
Abionyx is a publicly listed company based in Balma (France) founded in 2005. Therapeutics for rare diseases and severe inflammatory conditions are developed. Abionyx has raised $154.53 million across 7 funding rounds from investors including Orbimed, IXO and IRDI Capital Investissement. The company has 51 employees. Abionyx has completed 1 acquisition, including Iris Pharma. Its chief executive, as recorded, is Cyrille Tupin. Abionyx offers products and services including CER 001, CER 002, CER 209, and HDL Vectors. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is ABIONYX Pharma.
Company details
Developer of therapeutics for treating rare diseases and severe inflammatory conditions. The pipeline includes CER001 a recombinant apoAI HDL-mimetic under investigation for cardiovascular, rare genetic LCAT deficiency, severe inflammatory states, and even targeted delivery in oncology, CER-002 a peroxisome proliferator-activated receptor (PPAR) delta specific agonist in development for the treatment of cardiovascular diseases, and CER-209 is a oral P2Y13 receptor agonists for the treatment of atherosclerois and of non-alcoholic steato-hepatitis.
- Headquarters Balma, France
- Employees 51
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abionyx.com
- Social LinkedIn X
- Legal Name Abionyx Pharma Sa
- Annual Revenue$4.77 M (USD)-10.72as on Dec 31, 2025
- Net Profit-$6.52 M (USD)-26.68as on Dec 31, 2025
- EBITDA-$6.7 M (USD)-11.97as on Dec 31, 2025
- Total Equity Funding$154.53M (USD)
in 7 rounds
- Latest Funding Round$4.76M (USD), Post-IPO
Dec 2021
- InvestorsOrbimed
& 9 more
- Employee Count51
- Investments & Acquisitions
Products & Services of Abionyx
Abionyx offers a comprehensive portfolio of products and services, including CER 001, CER 002, CER 209, and HDL Vectors.
Drug for treating LCAT deficiency and related conditions
Treatment targeting sepsis and associated issues
Therapy for COVID-related complications
Vectors for targeted drug delivery in various diseases
Funding Insights of Abionyx
Abionyx has successfully raised a total of $154.53M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.76 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $154.53M
- Total Rounds 7
- Last Round Post-IPO — $4.76M
- First Round $30.5M
(Aug 2005)
- Investors Count 10
All 7 funding rounds of Abionyx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $4.76M | Post-IPO | – | – | – |
| Mar 2015 | $4.12M | Series C | – | – | – |
| Oct 2010 | $13.87M | Series C | – | IXO | |
| Jul 2010 | $13.81M | Grant | – | – | – |
| Jul 2010 | $52M | Series C | – | Daiwa Corporate Investment | |
| Nov 2006 | $54.04M | Series B | – | Orbimed, TVM Capital Life Science | |
| Aug 2005 | $30.5M | Series A | – | Healthcap, Alta Partners | – |
10 investors in total: 10 institutional.
Investors in Abionyx
Abionyx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, IXO and IRDI Capital Investissement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in France are managed by IXO. | ixope.fr | Toulouse, France | ||
Investment services are provided to startups, SMEs, and ETI in South-West France. | 1981 | irdi.fr | Toulouse, France | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage US tech and life science companies are invested in. | edfvc.com | Ann Arbor, United States | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
| healthcap.eu | ||||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital services are provided to support startups and innovation. | daiwa-inv.co.jp | Tokyo, Japan | ||
Life Science focused early stage VC firm investing in Europe, Canada, the USA and Asia | tvm-lifescience.com | Munich, Germany | ||
| nif.co.jp |
Investor details for Abionyx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abionyx
1 people are tracked at Abionyx (1 in leadership); the tracked headcount is 51.
| Name | Role | Group |
|---|---|---|
Cyrille Tupin | CEO | Leadership |
Complete people profiles for Abionyx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Abionyx
Abionyx is a publicly listed company on the EURONEXT with ticker symbol ABNX in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Mar 2015
- Listed onEuronext: ABNX
- Listed entityABIONYX Pharma SA
- Exchange sectorHealth technology
- ISINFR0012616852
- Share price1.46 EUR (+1.68% on the day) · 2026-10-14
- Market capitalisation62,776,222.00 EUR
- EPS (diluted, trailing year)-0.22 EUR
- Volume (last session)26,012
Financials of Abionyx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.1M EUR | -5.5M EUR | -5.7M EUR |
| 2024 | 4.5M EUR | -4.4M EUR | -5.1M EUR |
| 2023 | 4.6M EUR | -3.5M EUR | -5.0M EUR |
| 2022 | 5.2M EUR | -4.2M EUR | -5.0M EUR |
| 2021 | 675,000 EUR | -5.8M EUR | -7.6M EUR |
Detailed financial statements for Abionyx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abionyx
Abionyx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Iris Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A contract research organization offering preclinical and clinical research services to ophthalmology companies | iris-pharma.com | La Gaude, France | 1989 | Nov 2021 | •••• |
Complete acquisition details for Abionyx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abionyx
5 dated milestones of Abionyx across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Abionyx is founded.
- Funding First funding round of $30.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Iris Pharma.
- Funding Latest funding round, Post-IPO, of $4.8M.
Web traffic of Abionyx
The website of Abionyx (abionyx.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▼ 20.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abionyx
Complete news archive for Abionyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abionyx
Abionyx was founded in 2005.
Abionyx is headquartered in Balma, France. It is registered at Balma, Occitanie, France.
Cyrille Tupin is the CEO of Abionyx, as recorded in our data.
Abionyx is a funded company, having raised a total of $154.53M across 7 funding rounds to date. The company's 1st funding round was a Series A of $30.5M, raised on Aug 2005.
Abionyx has 51 employees.
Annual revenue of Abionyx is $4.77M as on Dec 31, 2025.
Developer of therapeutics for treating rare diseases and severe inflammatory conditions. The pipeline includes CER001 a recombinant apoAI HDL-mimetic under investigation for cardiovascular, rare genetic LCAT deficiency, severe inflammatory states, and even targeted delivery in oncology, CER-002 a peroxisome proliferator-activated receptor (PPAR) delta specific agonist in development for the treatment of cardiovascular diseases, and CER-209 is a oral P2Y13 receptor agonists for the treatment of atherosclerois and of non-alcoholic steato-hepatitis.
Abionyx offers CER 001, CER 002, CER 209, and HDL Vectors.
Yes, Abionyx is publicly traded on EURONEXT under the ticker symbol ABNX.
Abionyx has made 1 acquisition, including Iris Pharma.
Abionyx has 10 investors. Key investors include Orbimed, IXO, IRDI Capital Investissement, EDF Ventures, and Sofinnova Partners.
Abionyx operates through Abionyx Pharma.